AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03627910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc and arginine
Description: Feed supplementation
Study NCT04351841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arabinogalactan
Description: A beverage will be prepared by thoroughly mixing the 15 g of arabinogalactan with water and Crystal Light flavoring
Study NCT04351841 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: A beverage will be prepared by thoroughly mixing the 15 g of maltodextrin with water and Crystal Light flavoring
Study NCT00722631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Subjects who meet eligibility criteria will be titrated up to a maximum of 30 mg/day pioglitazone.
Study NCT00722631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Subjects who meet eligibility criteria will be titrated up to a maximum of 4 mg/day glimepiride.
Study NCT02971982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab /Dexamethasone/cyclophosphamide
Description: rituximab:375mg/m2 ,Dexamethasone 20mg q12h,cyclophosphamide 750mg
Study NCT02971982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade/Dexamethasone/cyclophosphamide
Description: Velcade:1.3mg/m2,Dexamethasone 10mg q12h,cyclophosphamide 750mg
Study NCT02212522 — intervention group
Intervention type: OTHER
Intervention: Collect of environmental data on T1D patients before diagnosis
Description: Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
Study NCT02212522 — intervention group
Intervention type: GENETIC
Intervention: Collect of blood samples for DNA extraction and genetic characterization (GWAS)
Description: Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
Study NCT02212522 — intervention group
Intervention type: OTHER
Intervention: Collect of clinical data on the disease and its evolution
Description: Collect of clinical data on the disease and its evolution every 6 months after enrollment
Study NCT02212522 — intervention group
Intervention type: OTHER
Intervention: Collect of environmental data on French controls (age-matched for T1D patients)
Description: Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
Study NCT00947817 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ULTRASONOGRAPHY trans-esophageal and trans-thoracic , blood test and clinic test
Study NCT00947817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ULTRASONOGRAPHY trans-esophageal and trans-thoracic , blood test and clinic test
Study NCT01793441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered in different stages of the study for 12 weeks.
Study NCT01793441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG7314
Description: RG7314 will be administered orally at a dose of 1.5 mg/day in Stage I, 4 mg/day in Stage II, 10 mg/day in Stage III and 1.5 mg/day or 10 mg/day in Stage IV for 12 weeks.
Study NCT00738699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MORAb-003 (farletuzumab)
Description: Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
Study NCT00589849 — intervention group
Intervention type: PROCEDURE
Intervention: T-wave Alternans
Description: T-wave alternans is an electrocardiographic finding that is defined as the beat-to beat fluctuation in the amplitude or shape of T wave
Study NCT04035798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine or placebo
Description: BP-II patients who are older than 40 years old will be recruited, and allocate them to add-on memantine or placebo plus standard valproic acid treatment in a 1: 1 ratio. The participants will receive memantine 5mg/day or placebo treatment for 12 weeks.
Study NCT04035798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine or placebo
Description: BP-II patients who are older than 40 years old will be recruited, and allocate them to add-on memantine or placebo plus standard valproic acid treatment in a 1: 1 ratio. The participants will receive memantine 5mg/day or placebo treatment for 12 weeks.
Study NCT04993261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual-Energy Computed Tomography
Description: Undergo dual energy CT scan
Study NCT02887833 — intervention group
Intervention type: OTHER
Intervention: Clinical biomarker (thermal sensory testing)
Description: Thermal sensitivity testing: The area of CIBP and a corresponding unaffected (control) area will be assessed using warm and cool thermal rollers (Rolltemp, Somedic, Sweden). The control area will either be the contralateral side, or an area proximal to the affected site.
Study NCT01899261 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SBRT
Study NCT00084383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX pancreatic cancer vaccine
Description: Patients will receive vaccinations consisting of 5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth booster vaccination, six months following the fourth vaccination.
Study NCT03893370 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RejuvenAir System
Description: RejuvenAir Metered CryoSpray
Study NCT03893370 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control Procedure
Description: Sham Control Procedure
Study NCT03816384 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care urinary drainage system.
Study NCT03816384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DLC Group
Description: Urinary drainage system with active drain line clearance and plain silicone catheter.
Study NCT03816384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DLCS Group
Description: Urinary drainage system with active drain line clearance and silver-doped silicone catheter.
Study NCT03656432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPP-ACP paste
Description: The complex CPP-ACP derived from a milk protein called casein. CPP-ACP represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
Study NCT03656432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPP-ACP paste
Description: The complex CPP-ACP derived from a milk protein called casein. CPP-ACP represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
Study NCT02040818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tigecycline, N-acetylcysteine, heparin combination
Study NCT02040818 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: guide-wire exchange
Study NCT01794819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-reactive protein test
Description: Results provides within 5 minutes. This test is based on solid-phase sandwich immunometric analysis. The measurement range in whole blood samples is 8-200 mg/L.
Study NCT02648724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym015
Description: Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.
Study NCT01218269 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: nitinol u-clip
Description: The U-clip is comprised of nitinol, an alloy of nickel and titanium.
Study NCT00831025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy with modified extract of Olea europaea pollen
Description: Subcutaneous immunotherapy with modified extract of Olea europaea. A subcutaneous monthly treatment.
Study NCT02556593 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Daily IMRT at 45 Gy in 15 fractions to brain metastases
Study NCT02878382 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional MAL-PDT
Description: Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
Study NCT02556593 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WBRT
Description: 3DCRT at 30 Gy in 10 fractions to whole brain
Study NCT02878382 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Calcipotriol assisted MAL-PDT
Description: Calcipotriol 50 mcg/g for 15 days prior to PDT. Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
Study NCT01710566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 600 mcg oral misoprostol to be administered after delivery of baby and before placenta is expelled
Study NCT01710566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 10 IU oxytocin in Uniject will be administered after delivery of baby and before placenta is expelled
Study NCT03402841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg twice daily - oral
Study NCT02993263 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: VectraplexECG System with CEB®
Description: The device will be used after noncardiac surgery
Study NCT00365807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positively Fit
Description: 12-week group intervention for children with obesity and their parents/caregivers
Study NCT00365807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief Family Intervention (Primarily education)
Description: 3 hours of contact with registered dietician for education and nutritional counseling.
Study NCT02556593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: erlotinib 150mg daily
Study NCT02175771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fp MDPI
Description: Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either 100 mcg or 200 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 400 mcg. Study drug was administered in the morning and in the evening.
Study NCT01634152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 actuations once daily in the evening
Study NCT01634152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium low dose mcg
Description: 2 actuations once daily in the evening
Study NCT01634152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium high dose
Description: 2 actuations once daily in the evening
Study NCT03615885 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Montmorency Tart Cherry Capsules
Description: Capsules are made from 100% natural, tart Montmorency cherries. Carefully prepared Montmorency cherry skins are freeze-dried and milled into a fine powder to protect the cherry phytonutrients and optimise absorbtion. This powder is then encapsulated into a 100% vegetarian shell.
Study NCT03615885 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Montmorency Tart Cherry Juice
Description: 100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.~Concentrate contains no sweeteners, preservatives, flavourings or added sugar.
Study NCT03615885 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 130ml serving~Placebo composition: Water (100ml), Cherry Cordial Concentrate (30ml), Citric Acid (1.5g), Maltodextrin (24.75g), Black Food Colouring (2ml).
Study NCT02175771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FS MDPI
Description: FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either Fp/Sx MDPI 100/12.5 mcg or Fp/Sx MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg Fp/Sx. Study drug was administered in the morning and in the evening.
Study NCT02175771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOVENT HFA
Description: FLOVENT HFA is a hydrofluoroalkane (HFA) inhaler containing fluticasone propionate.~During the treatment period, participants were randomized to either 110 mcg or 220 mcg of FLOVENT two puffs, twice a day for a total daily dose of 440 mcg or 880 mcg. Study drug was administered in the morning and in the evening.
Study NCT02175771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVAIR DISKUS
Description: ADVAIR DISKUS contains a dry powder formulation of fluticasone propionate (Fp) and salmeterol xinafoate (Sx) in a lactose excipient.~During the treatment period, participants were randomized to Fp 250 mcg/Sx 50 mcg or Fp 500 mcg/Sx 50 mcg one inhalation, twice a day for a total daily dose of 500/100 mcg or 1000/100 mcg. Study drug was administered in the morning and in the evening.
Study NCT02175771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol/salbutamol HFA
Description: A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
Study NCT02175771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol HFA
Description: A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
Study NCT03191006 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MEI BIN insoles
Description: insoles
Study NCT00738699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
Study NCT00738699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT00738699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Study NCT03179722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication review
Description: The intervention consists of a medicines use review provided by community pharmacists in Belgium. A medicines use review is a medication review type 2a in which both a patient interview and dispensing data are used as information sources to identify drug-related problems with a specific focus on the medicines use of the patient.
Study NCT03179722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional data collection: questionnaires
Description: Pre-post study design.~At three timepoints, data is collected:~* before the medication review (T-1week)~* during the review (Tweek 3)~* after the review (Tweek12) The questionnaire provide data for the outcomes: medication related quality of life, adherence questionnaire, service satisfaction, use of emergency health services, self-management
Study NCT03789786 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gait and Motion Analysis
Description: Gait and motion analysis is comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)
Study NCT03789786 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gross Motor Function Measure (GMFM)
Description: Gross Motor Function Measure (GMFM) is an assessment used to evaluate gross motor function over time in individuals with cerebral palsy. The assessment is comprised of movement activities like standing, walking, running, and jumping
Study NCT04052165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glaucoma Implant
Study NCT03789786 — intervention group
Intervention type: BEHAVIORAL
Intervention: Surveys
Description: Six surveys are used to assess function, activity, participation, pain, quality of life, and treatment history
Study NCT03185780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture: the insertion of use of ultra-fine needles (diameter 0.18 - 0.30mm) into designated acupoints in the skin, along the limbs and trunk areas.~Reflexology: The massage + application of localized pressure on designated points along the plantar aspect of the feet.~Shiatsu: The application of localized pressure along designated points (similar to acupoints) along the limbs and trunk areas.
Study NCT03411278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Oscillation (DO)
Description: DO self treatment with the device mobile (Physiomed, Laipersdorf, Germany; U.S. patent 7,343,203 B2).The device produces an alternating electrostatic field, which results in a low-frequency vibration penetrating the tissue. The Field is pulsed at a frequency of 90 Hz. For self-treatment, each volunteer is given an apparatus to take home. An applicator with a diameter of 9 cm is used. The treatment will be carried out in the morning and evening for 15 minutes each in supine position on a sofa. In accordance with the technique of classical manual lymphatic drainage, stroking and circular movements in the upper and lower leg and the inguinal area take place in a fixed order.
Study NCT03195426 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: distal nerves blocks group
Description: * ICB: US probe will be placed just below clavicle inferior to site of needle entry. Following identification of axillary artery and cords, the needle will be advanced posterior to axillary artery. 20 cc of Ropivacaine 0.375% will then be deposited in a U-shaped distribution posterior and to each side of the axillary artery.~* SSNB will be performed by locating the brachial plexus and the departure of the suprascapular nerve from the superior trunk under the inferior belly of the omohyoid muscle by sliding the transducer distally and then injecting 5 mL of ropivacaine 0.375%.~* SCNB will be performed injecting 5 mL of ropivacaine 0.375% in the intermuscular plane between the sternocleidomastoid and scalene muscles using a lateral to medial in-plane technique.
Study NCT03195426 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diaphragmatic function assessment
Description: Diaphragmatic excursion will be assessed under ultrasound immediately before and after regional anesthesia.~This a pain free and safe procedure, that we usually perform in patients at risk of respiratory failure.
Study NCT03692013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Participants will be divided into 2 groups as daytime group and nighttime group The participants in daytime group will take 100-200mg Losartan in the morning between 6AM to 8AM. The participants in nighttime group will take 100-200mg Losartan at night between 9PM to 11PM .
Study NCT03692013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Participants will be divided into 2 groups as daytime group and nighttime group The participants in daytime group will take 100-200mg Losartan in the morning between 6AM to 8AM. The participants in nighttime group will take 100-200mg Losartan at night between 9PM to 11PM .
Study NCT03854253 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long introducer sheath
Description: The investigators will perform transradial coronary angiography and percutaneous coronary interventions using introducer sheath 6Fr-25cm
Study NCT03418857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yogurt smoothie with BB-12
Description: During the one month intervention period, the participants will consume one yogurt smoothie with BB-12 daily.
Study NCT03418857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yogurt smoothie
Description: During the one month control period, the participants will consume one yogurt smoothie daily.
Study NCT02011919 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Echopulse
Description: HIFU Under ultrasound guidance
Study NCT03854253 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short introducer sheath
Description: The investigators will perform transradial coronary angiography and percutaneous coronary interventions using introducer sheath 6Fr-10cm
Study NCT00711126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444
Description: 2.5mcg IV